Sialorrhea – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Sialorrhea, also termed ptyalis or drooling, is an incapacitating phenomenon characterized by an excess accumulation of saliva in the oral cavity extending beyond the labial boundary. While drooling is common in typically developing infants, its prevalence diminishes between 15 to 36 months of age with the establishment of salivary control. Post the age of 4; this condition is regarded as abnormal. Pathological sialorrhea may arise as an isolated event due to heightened salivary secretion or may manifest concomitantly with various neurological conditions like amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), cerebral palsy (CP), or as an adverse effect of medications. In the pediatric population, CP is the leading cause of sialorrhea, persisting in 10%–38% of affected individuals. Conversely, PD is the predominant etiological factor in adults, accounting for sialorrhea in 70%–80% of PD patients. Notably, using clozapine in schizophrenic patients results in hypersalivation in 30%–80% of cases. Irrespective of the causative factor, drooling gives rise to clinical and functional complications, including impaired social functioning due to feelings of embarrassment and isolation, the potential for aspiration, skin integrity compromise, unpleasant odor, and susceptibility to infections. The principal salivary glands, encompassing the parotid, submandibular, and sublingual glands, play a vital role in the human body. Among these, the parotid gland is the largest. Saliva, secreted by these glands, is critical in lubrication, digestion, immune function, and overall homeostasis. In the unstimulated state, the submandibular and sublingual glands contribute 70% of total saliva production. Sialorrhea may emanate from augmented salivary generation due to idiopathic or drug-induced factors or mechanisms impeding the effective clearance of saliva from the oral cavity. Neurological disorders are often linked to sialorrhea, primarily stemming from compromised swallowing due to impaired neuromuscular coordination. This intricate coordination involves the harmonious interplay of structures encompassing the oral cavity, pharynx, larynx, and esophagus. In pediatric neurologic disorders, drooling appears to be more attributed to inefficiencies in tongue and bulbar control rather than an escalation in salivary secretion. Conservative therapeutic approaches entail modifications in dietary patterns or behaviors, oral-motor exercises, utilization of intra-oral devices like palatal training apparatuses, and medical interventions such as pharmacotherapy or botulinum toxin injections. Behavior modification strategies have been recommended for an extended period, although outcomes have demonstrated variability and necessitate a substantial time commitment. Invasive measures encompass surgical interventions or radiation therapy.

Thelansis’s “Sialorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sialorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Sialorrhea across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Sialorrhea Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Sialorrhea – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Familial Chylomicronemia Syndrome (FCS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder caused by mutations in the lipoprotein lipase gene, leading to hypertriglyceridemia and chylomicron accumulation in plasma. High triglycerides can result in complications like acute pancreatitis. FCS is also known as Lipoprotein lipase deficiency (LPLD), Type 1 hyperlipoproteinemia, and Endogenous hypertriglyceridemia. Diagnosis is based on fasting triglyceride levels exceeding 750 mg/dL and can be confirmed through genetic testing. Symptoms can emerge in infancy, childhood, or adolescence, with some patients remaining asymptomatic until adulthood. Common signs include Lipemia Retinalis (milky appearance in retinal veins), eruptive xanthomas (skin bumps with fatty deposits), abdominal pain, milky blood, and pancreatitis. Repeated pancreatitis is a severe complication that can lead to long-term pancreatic dysfunction and potential fatality if left untreated. FCS patients face a higher risk of pancreatiti...
Read more